CAPPELLI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.189
AS - Asia 9.244
EU - Europa 7.266
SA - Sud America 1.045
AF - Africa 243
OC - Oceania 123
Totale 28.110
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.988
RU - Federazione Russa 3.072
SG - Singapore 2.848
CN - Cina 2.820
IT - Italia 1.033
HK - Hong Kong 937
KR - Corea 872
BR - Brasile 805
VN - Vietnam 772
PL - Polonia 619
IE - Irlanda 515
FI - Finlandia 458
SE - Svezia 343
DE - Germania 334
FR - Francia 277
IN - India 251
GB - Regno Unito 174
BD - Bangladesh 137
AU - Australia 122
JP - Giappone 115
ID - Indonesia 111
NL - Olanda 110
AR - Argentina 91
JO - Giordania 91
TR - Turchia 85
CA - Canada 83
ES - Italia 79
MX - Messico 79
NG - Nigeria 51
EG - Egitto 50
UA - Ucraina 49
EC - Ecuador 42
ZA - Sudafrica 39
IQ - Iraq 36
PK - Pakistan 34
PT - Portogallo 33
CH - Svizzera 32
VE - Venezuela 25
AT - Austria 24
BJ - Benin 23
SA - Arabia Saudita 22
CL - Cile 21
BE - Belgio 19
CO - Colombia 19
LT - Lituania 18
MA - Marocco 17
DK - Danimarca 15
PY - Paraguay 15
UZ - Uzbekistan 15
KE - Kenya 14
MY - Malesia 14
CI - Costa d'Avorio 12
TN - Tunisia 12
AE - Emirati Arabi Uniti 10
PH - Filippine 9
AL - Albania 8
BO - Bolivia 8
NP - Nepal 8
PA - Panama 8
PE - Perù 8
UY - Uruguay 8
GR - Grecia 7
CR - Costa Rica 6
CZ - Repubblica Ceca 6
DZ - Algeria 6
BG - Bulgaria 5
BH - Bahrain 5
JM - Giamaica 5
KZ - Kazakistan 5
LV - Lettonia 5
NO - Norvegia 5
RS - Serbia 5
TW - Taiwan 5
AZ - Azerbaigian 4
BW - Botswana 4
HR - Croazia 4
KG - Kirghizistan 4
NI - Nicaragua 4
PS - Palestinian Territory 4
RO - Romania 4
TH - Thailandia 4
BY - Bielorussia 3
HN - Honduras 3
IR - Iran 3
LB - Libano 3
PR - Porto Rico 3
QA - Qatar 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
AO - Angola 2
CG - Congo 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GY - Guiana 2
IL - Israele 2
KW - Kuwait 2
LK - Sri Lanka 2
MD - Moldavia 2
MU - Mauritius 2
OM - Oman 2
Totale 28.082
Salva come PNG Salva come JPEG
Città #
Santa Clara 2.637
Singapore 2.164
Ashburn 1.417
Hefei 1.076
Seoul 869
Hong Kong 832
Warsaw 611
San Jose 523
Dublin 512
Fairfield 488
Helsinki 324
Beijing 290
Ho Chi Minh City 254
Chandler 253
Council Bluffs 226
Los Angeles 202
Woodbridge 200
Houston 192
Seattle 186
Moscow 174
Hanoi 171
New York 166
Lauterbourg 164
Cambridge 160
Buffalo 156
The Dalles 156
Florence 152
Wilmington 148
Kent 135
Munich 131
Melbourne 114
Lawrence 103
Altamura 100
Dallas 99
Ann Arbor 95
Tokyo 93
Milan 86
Jakarta 82
Rome 79
São Paulo 79
Mumbai 77
Princeton 74
Shanghai 72
Chicago 62
Lappeenranta 59
Bengaluru 58
Boston 57
Frankfurt am Main 53
Abuja 48
San Diego 48
Turku 47
Phoenix 44
Orem 43
Medford 42
Da Nang 41
Guangzhou 39
Amsterdam 38
London 38
Paris 36
Rio de Janeiro 36
West Jordan 36
Naples 34
Chennai 30
Düsseldorf 30
Haiphong 28
Istanbul 28
Boardman 27
Denver 27
Brooklyn 26
Montreal 26
Redondo Beach 25
Yubileyny 25
Asheville 24
Dong Ket 24
Jacksonville 24
Lisbon 24
Mexico City 24
Pune 24
Shenzhen 24
Cotonou 23
Stockholm 23
San Francisco 22
Johannesburg 21
Toronto 21
Atlanta 20
Bern 20
Belo Horizonte 19
Bologna 19
Brussels 18
Baghdad 17
Biên Hòa 17
Hillsboro 17
New Delhi 17
Nuremberg 17
Pisa 17
Poplar 17
Barcelona 16
Brasília 16
Cairo 16
Clifton 16
Totale 17.810
Salva come PNG Salva come JPEG
Nome #
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy 514
Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: An Italian perspective 289
Semi-quantitative indices of cardiac uptake in patients with suspected cardiac amyloidosis undergoing 99mTc-HMDP scintigraphy 287
Lung uptake during 99mTc-hydroxymethylene diphosphonate scintigraphy in patient with TTR cardiac amyloidosis: An underestimated phenomenon 264
Biohumoral markers as predictor of right ventricular dysfunction in AL Amyloidosis. 232
Different NT-proBNP circulating levels for different types of cardiac amyloidosis 227
Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis 220
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 217
Standard Therapy in Cardiac Amyloidosis 211
Real-world versus trial patients with transthyretin amyloid cardiomyopathy 210
Clinical staging of Anderson-Fabry cardiomyopathy: An operative proposal 206
Heart failure with mid-range ejection fraction: Current evidence and uncertainties 206
Cardiac Resynchronization Therapy for End-Stage Hypertrophic Cardiomyopathy: The Need for Disease-Specific Criteria 200
[Therapeutic approaches in hypertrophic cardiomyopathy: from symptom relief to precision therapy] 198
Determinants of health status in older patients with transthyretin cardiac amyloidosis: a prospective cohort study 197
Incidence and determinants of atrial fibrillation in patients with wild-type transthyretin cardiac amyloidosis 196
Screening for cardiac amyloidosis in patients with tenosynovial red flags: A collaboration between family medicine and cardiology 195
Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis 194
A multidisciplinary case report of multiple myeloma with renal and cardiac involvement: a look beyond amyloidosis 194
As we cannot afford to renounce to new generation echocardiography in systemic amyloidosis. 189
Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis 187
Clinical pathway for cardiomyopathies: A genetic testing strategy proposed by ANMCO in Tuscany 185
Cerebral Fat Embolism After Video-Assisted Thoracic Surgery 185
Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis 185
Troponins in cardiac amyloidosis: multipurpose markers. 183
Liver dysfunction as predictor of prognosis in patients with amyloidosis: utility of the Model for End-stage Liver disease (MELD) scoring system 183
Results of comprehensive cardiovascular diagnostic work-up in HIV positive patients 182
Depression and cardiac symptoms among AL amyloidosis patients: the mediating role of coping strategies. 181
Arrhythmic Burden in Cardiac Amyloidosis: What We Know and What We Do Not 180
Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience 179
Electromechanical dissociation of left atrium in patients with Cardiac Amyloidosis by Magnetic Resonance: Prognostic and clinical correlates 178
Abrupt onset of refractory heart failure associated with light-chain amyloidosis in hypertrophic cardiomyopathy 177
Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary Referral Centre in Tuscany 177
Serial changes in CPET parameters in untreated patients with transthyretin cardiac amyloidosis 176
Anxiety and depression among amyloid light-chain cardiac amyloidosis patients: The role of life satisfaction. 176
Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis 175
Red flags for the diagnosis of cardiac amyloidosis: Simple suggestions to raise suspicion and achieve earlier diagnosis 175
ECG abnormalities, atrial fibrillation and AV blocks in ATTR VS AL amyloidosis: an electrophysiological natural history 175
Prevalence of transthyretin-related amyloidosis in Tuscany: Data from the regional population-based registry 173
Amyloidosis in spinal stenosis: How, when and whether cardiac screening has a clinical impact 171
Poor right ventricular function is associated with impaired exercise capacity and ventilatory efficiency in transthyretin cardiac amyloid patients 171
Incidence of stroke in patients with hypertrophic cardiomyopathy in stable sinus rhythm during long-term monitoring 169
QRS duration in left bundle branch block does not affect left ventricular twisting in chronic systolic heart failure 169
Multicentre multi-device hybrid imaging study of coronary artery disease: Results from the EValuation of INtegrated Cardiac Imaging for the Detection and Characterization of Ischaemic Heart Disease (EVINCI) hybrid imaging population 168
Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy 168
The Role of T2 Mapping in Cardiac Amyloidosis 164
Temporal Variation in Optimal Atrioventricular and Interventricular Delay During Cardiac Resynchronization Therapy 164
Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study 164
Epigallocatechin-3-gallate tolerability and impact on survival in a cohort of patients with transthyretin-related cardiac amyloidosis. A single-center retrospective study 164
Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis 163
Investigation on the high recurrence of the ATTRv-causing transthyretin variant Val142Ile in central Italy 162
A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization - the first insight from the AC-TIVE Study 162
Measurement of myocardial amyloid deposition in systemic amyloidosis: Insights from cardiovascular magnetic resonance imaging 161
Emerging Medical Treatment for Hypertrophic Cardiomyopathy 161
Concordant Versus Discordant Left Bundle Branch Block in Heart Failure Patients: Novel Clinical Value of an Old Electrocardiographic Diagnosis 160
Caregiver’s psychological well-being and quality of relationship with cardiac amyloidosis patients 160
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey 160
Anxiety and depression among AL amyloidosis patients: The role of cardiac symptoms 160
Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis 160
Aortic Stenosis and Cardiac Amyloidosis: PARTNERs in Crime? 159
Clinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid Cardiomyopathy 159
Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis 159
Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems 159
Atrial standstill disease progression documented after 13 years follow-up 159
Echo/Doppler-derived time intervals are able to predict left ventricular reverse remodeling after cardiac resynchronization therapy 157
Prognostic value of cardiopulmonary exercise testing in patients with transthyretin cardiac amyloidosis 156
Early Diagnosis and Outcome in Patients With Wild-Type Transthyretin Cardiac Amyloidosis 156
Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis 155
Clinical scenarios of HCM-related mortality: Relevance of age and stage of disease at presentation 155
Anxious/Depressive Symptoms Alter the Subjective Perception of Heart Failure Severity in Transthyretin Cardiac Amyloidosis 155
Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathy 155
Transthyretin Cardiac Amyloidosis: A Cardio-Orthopedic Disease 154
ATTRv amyloidosis Italian Registry: clinical and epidemiological data 154
Tenosynovial complications identify TTR cardiac amyloidosis among patients with hypertrophic cardiomyopathy phenotype 154
Progressive and atypical neurological symptoms in refractory systemic AL amyloidosis 153
Differential Diagnoses in Clinical Mimics 153
Cardiac amyloidosis in patient undergoing TAVR, why we need to think about it 152
Is Hereditary Transthyretin Amyloidosis the Third Leading Cause of Monogenic Chronic Kidney Disease, Only Behind ADPKD and Alport Disease? 151
From atrial fibrillation management to atrial myopathy assessment: the evolving concept of left atrium disease in hypertrophic cardiomyopathy 150
SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series 150
The Italian Fabry Disease Cardiovascular Registry (IFDCR) 150
Wild-Type ATTR Amyloidosis 149
Diagnostic Pathways to Wild-Type Transthyretin Amyloid Cardiomyopathy: a Multicenter Network Study 149
Baseline ECG features and arrhythmic profile in transthyretin versus light chain cardiac amyloidosis 149
Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey 148
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial 148
The Val142Ile transthyretin cardiac amyloidosis: more than an Afro-American pathogenic variant 148
Rotational mechanics of the left ventricle in AL amyloidosis 148
Role of cardiovascular magnetic resonance in the clinical evaluation of left ventricular hypertrophy: a 360° panorama 147
Frailty and caregiver relationship quality in older patients diagnosed with transthyretin cardiac amyloidosis 146
Favourable outcome of Streptococcus agalactiae prosthetic valve endocarditis after conservative treatment 145
Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis 145
A Man in His 80s with Hypertension, Left Ventricular Hypertrophy, and Enlarged Biceps 145
Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value 144
Impact of Pregnancy on the Natural History of Women with Hypertrophic Cardiomyopathy 144
Has mechanical dyssynchrony still a role in predicting cardiac resynchronization therapy response 143
Prevalence and diagnostic value of extra-left ventricle echocardiographic findings in transthyretin-related cardiac amyloidosis 142
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy 142
Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives 142
Adaptative or maladaptative hypertrophy, different spatial distribution of myocardial contraction 141
Totale 17.509
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.607
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 82.607
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202191 0 0 0 0 0 0 0 0 0 0 49 42
2021/2022567 16 27 20 20 18 39 15 34 44 97 80 157
2022/20231.796 99 319 88 77 124 319 337 103 186 31 72 41
2023/20241.381 24 116 135 59 112 171 61 334 39 136 102 92
2024/20258.991 292 879 475 1.372 2.236 1.160 224 440 445 242 515 711
2025/202613.324 1.384 2.040 1.912 1.384 1.252 551 1.526 793 1.099 807 576 0
Totale 28.418